Fipamezole (JP-1730) is a potent α2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease

Movement Disorders

Volumn 18, Issue 8, 2003, Pages 872-883

  Savola, Juha Matti ^a   Hill, Michael ^b   Engstrom, Mia ^a   Merivuori, Hannele ^a   Wurster, Siegfried ^a   McGuire, Steven G ^b   Fox, Susan H ^c   Crossman, Alan R ^b,d   Brotchie, Jonathan M ^d,e  

^a Oy Juvantia Pharma Ltd   (Finland)

^b Williams House   (United Kingdom)

^c WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^d G38 Stopford Building   (United Kingdom)

^e UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

2 adrenergic; Dyskinesia; JP 1730; Marmoset

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 1,3,4,5',6,6',7,12B OCTAHYDRO 1',3' DIMETHYL 2H SPIRO[BENZO[B]FURO[2,3 A]QUINOLIZINE 2,4' PYRIMIDINE] 2' ONE; 2 (2 METHOXY 1,4 BENZODIOXAN 2 YL) 2 IMIDAZOLINE; ADRENALIN; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2A ADRENERGIC RECEPTOR; ALPHA 2B ADRENERGIC RECEPTOR; ALPHA 2C ADRENERGIC RECEPTOR; ANTIPARKINSON AGENT; ATIPAMEZOLE; BENSERAZIDE PLUS LEVODOPA; FIPAMEZOLE; GUANOSINE TRIPHOSPHATASE; HISTAMINE H1 RECEPTOR; HISTAMINE H3 RECEPTOR; IDAZOXAN; LEVODOPA; PRAZOSIN; RAUWOLSCINE; SEROTONIN TRANSPORTER; SULFUR 35; UNCLASSIFIED DRUG; YOHIMBINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BINDING SITE; BIOASSAY; CHO CELL; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DYSKINESIA; FEMALE; HUMAN; HUMAN CELL; MALE; MARMOSET; MEDICAL ASSESSMENT; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIMATE; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BINDING;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; ANTIPARKINSON AGENTS; BINDING, COMPETITIVE; CALLITHRIX; DYSKINESIA, DRUG-INDUCED; FEMALE; IMIDAZOLES; INDANS; LEVODOPA; MALE; PARKINSONIAN DISORDERS; RADIOLIGAND ASSAY; RATS; RECEPTORS, ADRENERGIC; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, AMPA; RECEPTORS, DOPAMINE; RECEPTORS, GABA; RECEPTORS, HISTAMINE; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, SEROTONIN;

EID: 0042474326     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10464     Document Type: Article

References (50)

1. Nutt JG, Levodopa induced dyskinesia: review. Observations and speculations. Neurology 1990;40:340-345.
2. Stocchi F, Nordera G, Marsden CD. Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias. Clin Neuropharmacol 1997;20:95-115.
3. Hurtig HI. Problems with current pharmacological treatment of Parkinson's disease. Exp Neurol 1997;144:10-16.
4. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000;342:1484-1491.
5. Pal PK, Samii A, Kishore A, Schulzer M, Mak E, Yardley S, Turnbull IM, Calne DB. Long term outcome of unilateral pallidotomy: follow-up of 15 patients for 3 years. J Neurol Neurosurg Psychiatry 2000;69:337-344.
6. Gross RE, Lombardi WJ, Lang AE, Duff J, Hutchison WD, Saintr JA, Tasker RR, Lozano AM. Relationship of lesion location to clinical outcome following microelectrode-guided pallidotomy for Parkinson's disease. Brain 1999;122:405-416.
7. Narabayashi H. Stereotactic surgery and Parkinson's disease. Stereotact Funct Neurosurg 1998;70:114-121.
8. Gross C, Rougier A, Guehl D, Boraud T, Julien J, Bioulac B. High-frequency stimulation of the globus pallidus internalis in Parkinson's disease: a study of seven cases. J Neurosurg 1997;87: 491-498.
9. Baron MS, Vitek JL, Bakay RA, Green J, McDonald WM, Cole SA, DeLong MR. Treatment of advanced Parkinson's disease by unilateral posterior GPi pallidotomy: 4-year results of a pilot study. Mov Disord 2000;15:230-237.
10. Fine J, Duff J, Chen R, Chir B, Hutchison W, Lozano AM, Lang AE. Long-term follow-up of unilateral pallidotomy in advanced Parkinson's disease. N Engl J Med 2000;342:1708-1714.
11. Durif F, Vidailhet M, Bonnet AM, Blin J, Agid Y. Levodopa-induced dyskinesias are improved by fluoxetine. Neurology 1995; 45:1855-1858.
12. Brotchie JM. Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov Disord 1998;13:871-876.
13. Gomez-Mancilla B, Bedard PJ. Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clin Neuropharmacol 1993;16:418-427.
14. Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2001;2:577-588.
15. Blanchet PJ, Konitsiotis S, Chase TN. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord 1998;13:798-802.
16. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998;50:1323-1326.
17. Rajput AH, Rajput A, Lang AE, Kumar R, Uitti RJ, Galvezmenez N. New use for an old drug: amantadine, benefits levodopa-induced dyskinesia. Mov Disord 1998;13:851.
18. Snow BJ, MacDonald L, McAuley D, Wallis W. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 2000;23:82-85.
19. Luginger E, Wenning GK, Bosch S, Poewe W. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov Disord 2000;15:873-878.
20. Crossman AR. An hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induce dyskinesia in Parkinson's disease: implications for future strategies in treatment. Mov Disord 1990;5:100-108.
21. Filion M, Tremblay L, Bedard PJ. Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res 1991;547: 152-161.
22. Mitchell IJ, Boyce S, Sambrook MA, Crossman AR. A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia. Brain 1992;115: 809-824.
23. Papa SM, Desimone R, Fiorani M, Oldfield EH. Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias. Ann Neurol 1999;46:732-738.
24. Brotchie JM. Advances in understanding the neural mechanisms underlying L-dopa-induced dyskinesia. Adv Neurol 1999;80:71-85.
25. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, Lanciego JL, Artieda J, Gonzalo N, Olanow CW. Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 2000;23: S8-S19.
26. Hill MP, Brotchie JM. The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat. Br J Pharmacol 1999;128:1577-1585.
27. Henry B, Crossman AR, Brotchie JM. Characterization of enhanced behavioral responses to L-dopa following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp Neurol 1998;151:334-342.
28. Henry B, Fox SH, Peggs D, Crossman AR, Brotchie JM. The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 1999; 14:744-753.
29. Fox SH, Henry B, Hill MP, Peggs D, Crossman AR, Brotchie JM. Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan. Mov Disord 2001;16:642-650.
30. Peyro-Saint-Paul H, Rascol O, Blin O, et al. A pilot study of idazoxan, an alpha2 antagonist, in Parkinson's disease. Mov Disord 1996;11(Suppl. 1):116.
31. Rascol OI, Arnulf C, Brefel M, et al. L-dopa-induced dyskinesias improvement by an α2 antagonist, idazoxan, in patients with Parkinson's disease. Mov Disord 1997;12:111.
32. Marjamaki A, Ala Uotila S, Luomala K, Perala M, Jansson C, Jalkanen M, Regan JW, Scheinin M. Stable expression of recombinant human alpha 2-adrenoceptor subtypes in two mammalian cell lines: characterization with [3H]rauwolscine binding, inhibition of adenylate cyclase and RNase protection assay. Biochim Biophys Acta 1992;1134:169-177.
33. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (150) of an enzymatic reaction. Biochem Pharmacol 1973;22:3099-3108.
34. Jasper JR, Lesnick JD, Chang LK, Yamanishi SS, Chang TK, Hsu SA, Daunt DA, Bonhaus DW, Eglen RM. Ligand efficacy and potency at recombinant alpha2 adrenergic receptors: agonist-mediated [35S]GTPgammaS binding. Biochem Pharmacol 1998;55: 1035-1043.
35. Pohjanoksa K, Jansson CC, Luomala K, Marjamaki A, Savola JM, Scheinin M. Alpha2-adrenoceptor regulation of adenylyl cyclase in CHO cells: dependence on receptor density, receptor subtype and current activity of adenylyl cyclase. Eur J Pharmacol 1997;335: 53-63.
36. Pearce RK, Jackson M, Smith L, et al. Chronic L-dopa administration induces dyskinesias in the 1-methyl-4- phenyl-1, 2, 3, 6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus). Mov Disord 1995;10:731-740.
37. Contin M, Riva R, Martinelli P, Baruzzi A. Kinetic-dynamic relationship of oral levodopa: possible biphasic response after sequential doses in Parkinson's disease. Mov Disord 1992;7:244-248.
38. Luquin MR, Scipioni O, Vaamonde J, Gershanik O, Obeso JA. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov Disord 1992;7:117-124.
39. Marconi R, Lefebvre CD, Bonnet AM, et al. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Mov Disord 1994;9:2-12.
40. Halme M, Sjholm B, Savola JM, Scheinin M. Recombinant human alpha 2-adrenoceptor subtypes: comparison of [3H]rauwolscine, [3H]atipamezole and [3H]RX821002 as radioligands. Biochim Biophys Acta 1995;1266:207-214.
41. O'Rourke MF, Blaxall HS, Iversen LJ, Bylund DB. Characterization of [3H]RX821002 binding to alpha-2 adrenergic receptor subtypes. J Pharmacol Exp Ther 1994;268:1362-1367.
42. Newman-Tancredi A, Nicolas JP, Audinot V, Gavaudan S, Verriele L, Touzard M, Chaput C, Richard N, Millan MJ. Actions of alpha2 adrenoceptor ligands at alpha2A and 5-HT1A receptors: the antagonist, atipamezole, and the agonist, dexmedetomidine, are highly selective for alpha2A adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 1998;358:197-206.
43. Lione LA, Nutt DJ, Hudson AL. Characterisation and localisation of [3H]2-(2-benzofuranyl)-2-imidazoline binding in rat brain: a selective ligand for imidazoline 12 receptors. Eur J Pharmacol 1998;353:123-135.
44. Nomecomt Study Group. Rinne UK, Larsen JP, Siden A, Worm-Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology 1998;51: 1309-1314.
45. Manson AJ, Iakovidou E, Lees AJ. Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease. Mov Disord 2000;15:336-337.
46. Unnerstall JR, Kopajtic TA, Kuhar MJ. Distribution of α2-agonist binding sites in the rat and human central nervous system: analysis of some functional anatomic correlates of the pharmacological effects of clonidine and related adrenergic agents. Brain Res 1984; 319:69-101.
47. Scheinin M, Lomasney JW, Hayden HD, et al. Distribution of α2-adrenergic receptor subtype gene expression in rat brain. Brain Res Mol Brain Res 1994;21:133-149.
48. Rosin DL, Talley EM, Lee A, et al. Distribution of alpha 2C-adrenergic receptor-like immunoreactivity in the rat central nervous system. J Comp Neurol 1996;372:135-165.
49. Kulatunga M, Scheinin M, Kotti T, et al. Coexistence of α2C-adrenoceptor immunoreactivity with GABA, calbindin D28K and parvalbumin immunoreactivity in rat striatal neurons. Soc Neurosci Abstr 1997;23:586.
50. Holmberg M, Scheinin M, Kurose H, Miettinen R. Adrenergic alpha2C-receptors reside in rat striatal GABAergic projection neurons: comparison of radioligand binding and immunohistochemistry. Neuroscience 1999;93:1323-1333.